Generic drug giant Mylan, which announced a restructuring this week to streamline operations, continues to work on a cost-cutting plan that could lead to additional job cuts, the company revealed in a government filing Wednesday.

Mylan said it announced the initial restructuring steps in “certain locations” on Monday.

“The company is currently developing the details of the cost reduction initiatives, including workforce actions and other potential restructuring activities beyond the programs already announced,” Mylan said in an 8K filing with the Securities and Exchange Commission.

The moves are expected to impact less than 10 percent of the company’s global workforce, the company said in the filing. Mylan employed some 35,000 workers and outside contractors at the end of last year.

Advertise with us

The company, which has its operations base in Cecil and its flagship manufacturing plant in Morgantown, W.Va., did not respond to emails seeking more details on the restructuring.

Mylan has been hurt in recent months by public and Congressional accusations of price-gouging over the cost of its EpiPen allergy shot, which has soared some 500 percent in recent years.

Last month, Mylan reported a nearly $120 million loss for the third quarter after taking a charge to reflect a proposed $465 million settlement with the U.S. Justice Department for overcharging Medicaid for the EpiPen.

Mylan’s shares have tumbled in recent months, falling about 26 percent since Aug. 1, just before the EpiPen scandal erupted.

Shares lost $1.36, or 3.79 percent, Wednesday to close at $34.50 on a day when some other pharmaceutical stocks also slumped amid comments by president-elect Donald Trump promising to slash drug prices.

Advertise with us

Mylan’s shares were trading in the high $60s in April 2015 just before Teva Pharmaceutical Industries offered to buy the company for $82 in cash and stock. The Israeli firm’s bid was quickly rejected.

“We believe that the current [stock market] environment is very sensitive about restructurings and headcount reductions, and [Mylan’s announcement] may represent another headline or sentiment risk” for the company, Wells Fargo senior analyst David Maris said in a note to clients Wednesday.

“That said, we believe a company should do what is best for the long run health of the company.”

Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.